report

The EBC releases its 2019 Annual Report

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

In this study recently published in the New England Journal of Medicine, the authors conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with candidate vaccine mRNA-1273 (which encodes the stabilised prefusion SARS-CoV-2 spike protein) in a dose of 25 μg, 100 μg, or 250 μg.

In this controlled, open-label trial recently published in the New England Journal of Medicine, the authors randomly assigned patients who were hospitalised with COVID-19 to receive either oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or usual care.

Fellowship project: Clinico-pathological correlations in FTD: a study in the Dutch population

Report from Dr Sandra Manuela Dias Moreira from Amarante, Portugal visiting Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, UK under the supervision of Dr. Teresinha Evangelista.

by Elena Lebedeva, Local Organizer in Yekaterinburg I am very grateful to European Academy of Neurology (EAN) for continuing   support of Regional Teaching courses (RTC) and great help and support of our EAN RTC in Yekaterinburg! I want to say… Continue Reading

The 8th RTC took place in Maputo, Mozambique from 10 to 12 November 2016 and was hosted by the Eduardo Mondlane University of Maputo. The RTC, organised by the EAN – European Academy of Neurology, was supported by a consortium of European and international scientific societies: